VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

ALVAC-NiV-F
Vaccine Information
  • Vaccine Name: ALVAC-NiV-F
  • Target Pathogen: Nipah virus
  • Target Disease: Nipah virus disease
  • Vaccine Ontology ID: VO_0004734
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • F fusion protein gene engineering:
    • Type: Recombinant vector construction
    • Description: Canarypox virus-based vaccine vectors carrying the gene for NiV glycoprotein (ALVAC-G) or the fusion protein (ALVAC-F) (Weingartl et al., 2006).
    • Detailed Gene Information: Click Here.
  • G glycoprotein gene engineering:
    • Type: Recombinant protein preparation
    • Description: Canarypox virus-based vaccine vectors carrying the gene for NiV glycoprotein (ALVAC-G) or the fusion protein (ALVAC-F) (Weingartl et al., 2006).
    • Detailed Gene Information: Click Here.
  • Vector: ALVAC vaccine vector
  • Preparation: Canarypox virus-based vaccine vectors carrying the fusion protein (ALVAC-F) (Weingartl et al., 2006).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Pig Response

  • Vaccination Protocol: Four pigs per group were intramuscularly challenged, with either with 108 PFU each or in combination of (ALVAC-NiV-G and ALVAC-NiV-F) (Weingartl et al., 2006).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: The pigs were challenged with 2.5 x 105 PFU of NiV two weeks later (Weingartl et al., 2006).
  • Efficacy: The combined ALVAC-F/G vaccine induced the highest levels of neutralization antibodies (2,560); despite the low neutralizing antibody levels in the F vaccinees (160), all vaccinated animals appeared to be protected against challenge (Weingartl et al., 2006).
References
Weingartl et al., 2006: Weingartl HM, Berhane Y, Caswell JL, Loosmore S, Audonnet JC, Roth JA, Czub M. Recombinant nipah virus vaccines protect pigs against challenge. Journal of virology. 2006; 80(16); 7929-7938. [PubMed: 16873250].